This article discusses the corporate mission, strategies, organizational leadership, and portfolio that PharmAthene (NYSEMKT:PIP) and Theraclone Sciences will create by merging. It explains why the combination will be synergistic and increase shareholder value. Because Theraclone Sciences is a privately-held company, I give more space to its programs: I explain the importance of monoclonal antibody therapeutics and the virtues of Thereaclone's I-STAR-its engine for discovering and developing promising monoclonal antibodies . I also provide an unorthodox rationale for putting a high priority on searching for better ways of dealing with Human Cytomegalovirus (CMV) infection.
I encourage you to work through any parts of this journey that may push you beyond your comfort zone: e.g., explanations of immunological concepts, the
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|